Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576276 | 0.87 | TRPV1 (0.55) | TRPV1LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL3575488 | 0.85 | TRPV1 (0.48) | TRPV1 | |
| SCHEMBL3572529 | 0.85 | TRPV1 (0.62) | TRPV1LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL13316530 | 0.82 | TRPV1 (0.54) | TRPV1LMNA | |
| SCHEMBL3575477 | 0.81 | TRPV1 (0.52) | TRPV1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3572064 | 0.81 | TRPV1 (0.52) | TRPV1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3574870 | 0.81 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL13316634 | 0.81 | TRPV1 (0.61) | TRPV1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL13316531 | 0.80 | TRPV1 (0.51) | TRPV1LMNA | |
| SCHEMBL13316529 | 0.79 | TRPV1 (0.52) | TRPV1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | TRPV1 30/4885LMNA 4055/4885KDM4E 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.